Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest zolpidem Stories

2009-08-14 05:35:00

RICHMOND, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience, today announced financial results for the three and six months ended June 30, 2009. Glenn A. Oclassen, President and Chief Executive Officer commented, "Our recently announced agreement with Purdue Pharmaceutical Products, L.P....

2009-08-06 07:30:00

RICHMOND, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will report results for its quarter ended June 30, 2009 on Friday, August 14, 2009, prior to the opening of the market. A conference call to review the results will begin at 8:30 a.m. ET (5:30...

2009-08-02 16:00:00

STAMFORD, Conn. and PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced entry into an exclusive license and collaboration agreement to commercialize Intermezzo((R)) (zolpidem tartrate sublingual tablet) in the United States. If approved by the U.S. Food and Drug Administration (FDA), Intermezzo((R)) has the potential to be the first prescription sleep aid specifically approved for use...

2009-07-22 08:00:00

RICHMOND, Calif., July 22 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the BMO Capital Markets Healthcare Conference in New York City on Wednesday, August 5, 2009 at 4:00 p.m.,...

2009-07-03 08:53:03

Why do some people who take the sleep aid Ambien sleepwalk and engage in other activities they don't recall in the morning?Researchers from Georgetown University Medical Center are helping explain the phenomenon. In an animal study, they found inhibitory neurons responsible for stopping neural activity are shut down by the drug. But excitatory neurons, which transmit activity, are free to wake up, and because the inhibitory neurons responsible for keeping them in check are effectively asleep...

2009-06-29 16:46:29

 Some people who take the fast-acting sleep-aid zolpidem (Ambien) have been observed walking, eating, talking on the phone and even driving while not fully awake. Many often don't remember doing any of these activities the next morning. Similarly, this drug has been shown to awaken the minimally conscious into a conscious state. A new study by Georgetown University Medical Center (GUMC) researchers may help explain why these "awakenings" occur.The study, published online in the...

2009-06-09 08:00:00

Analyses of Efficacy and Absence of Rebound Effect in a Clinical Study of Intermezzo(R) (Zolpidem Tartrate Sublingual Tablet 3.5 mg) to Treat Middle-of-the-Night (MOTN) Awakening on an As-Needed Basis RICHMOND, Calif., June 9 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today...

2009-05-21 08:00:00

Safety and Efficacy Study of Zolpidem Tartrate Sublingual Tablet in Treating Middle-of-the-Night Awakening on an As-Needed Basis Evaluation of Ondansetron Augmentation in the Treatment of Obsessive Compulsive Disorder RICHMOND, Calif., May 21 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience,...

2009-05-20 13:27:06

Cognitive behavior therapy and the medication zolpidem taken for six weeks improved sleep in those with persistent insomnia, Canadian researchers found. Charles M. Morin of the Universite Laval in Quebec City and colleagues evaluated the short- and long-term effects of cognitive behavior therapy singly and combined with the medication zolpidem, for persistent insomnia, and compared treatment strategies to optimize long-term outcomes. The trial included 160 adults, who were randomized to...

2009-05-20 06:59:28

People suffering from insomnia appear to benefit from cognitive behavior therapy (CBT). A recent study found CBT used alone or with the medication zolpidem (Ambien) led to significant improvements in the amount of time it took to fall asleep, the amount of times a person woke up during the night, and how well a person slept during the initial therapy. Researchers at the University Laval in Quebec, Canada, compared the short-term and long-term effects of CBT combined with the zolpidem on...